Eugeroics are a relatively new class of wakefulness-promoting agents. The group includes adrafinil, modafinil and armodafinil. Modafinil is the most widely used and the best studied agent. Indications for the use of modafinil include the treatment of narcolepsy, shift-work sleep disorders and excessive daytime sleepiness associated with obstructive sleep apnea. Many studies show the utility of modafinil and armodafinil in the treatment of depression -both in monotherapy and as potentiation therapy if needed. Modafinil has proven to be effective in the treatment of residual symptoms of unipolar and bipolar depression such as fatigue, excessive sleepiness and some cognitive impairment. Research on armodafinil points to its effectiveness mainly in augmentation therapy of depression in the course of bipolar disorder. There are also reports on the effectiveness of eugeroics in special cases -seasonal depression, atypical depression with hyperphagia, apathy in the course of depression or as an isolated symptom, cancer-related fatigue in patients receiving chemotherapy, fatigue and excessive sleepiness in neurological diseases. Eugeroics due to their high selectivity of action in the CNS have a low addictive potential compared with other stimulants. The risk of manic switch is comparable to placebo. In general, they are well-tolerated and safe. The purpose of this paper is to review the literature on the use of eugeroics in the treatment of affective disorders.
Introduction
Eugeroics are a group of drugs which are molecules that promote wakefulness. Adrafinil, synthesized in the mid-70s in France and used in experimental treatment of narcolepsy was a pro-molecule in this group. Modafinil is its active metabolite discovered 2 years later. It is a similar molecule, which, however, due to more promising results in animal studies has found wider use. Since the 1990s, both drugs have been consecutively introduced on the market to treat narcolepsy in France (1994) , in the USA (1998) and in the UK (2002) . In 2003, indications for the use of modafinil were extended to shift-work sleep disorders and excessive daytime sleepiness associated The purpose of many studies on eugeroics was to demonstrate their usefulness in the treatment of mood and psychomotor disorders, fatigue, excessive sleepiness, and cognitive impairment.
The use of eugeroics in affective disorders -a research review
Since the occurrence of modafinil and armodafinil on the market, numerous studies on their usefulness in the treatment of unipolar an bipolar depression both from the beginning and in the treatment of some residual symptoms, were carried out. The most common residual symptoms are typical depressive symptoms, but usually less severe: depressed mood, fatigue and lack of energy, sleep and sexual disorders, anxiety or somatic symptoms (e.g., pain).
Fatigue and excessive sleepiness
Modafinil as a wakefulness-promoting agent was expected to mainly affect improvement in fatigue and lack of energy as well as excessive sleepiness. Studies described in the literature checked the usefulness of modafinil in augmentation treatment of depression with fatigue and excessive sleepiness as a drug administered from the beginning or after different periods of antidepressant and mood-stabilizing treatment alone. To assess the results, most researchers used rating scales, such as: Hamilton Depression Rating Scale (HAM-D) and its Seasonal Affective Disorders Version (SIGH-SAD), Montgomery-Asberg Depression Rating Scale (MADRS), Fatigue Severity Scale (FSS), Brief Fatigue Inventory (BFI), Epworth Sleepiness Scale (ESS), Clinical Global Impressions Scale (CGI), Global Assessment of Functioning Scale (GAF).
Since about the year 2000, studies on modafinil were limited, conducted in small groups of patients and mostly open-label. Hence, the analysis of literature by Lam et al. [6] from 2007 does not unambiguously recommend modafinil as a treatment strategy for fatigue as a residual symptom of depression and suggests the need for more double-blind, randomized, placebo-controlled trials. Nevertheless, the analysis of individual studies from before 2007 reveals similar conclusions. In most of them, the improvement in fatigue and excessive sleepiness was rapid -in the first and second [7] [8] [9] (maximum fifth [10] ) week of modafinil administration, and persisted in the following weeks. Significant improvements in the FSS and ESS scales were observed in the first weeks [7, 8, [11] [12] [13] . In the further course of therapy, the differences between modafinil and placebo became statistically insignificant about week 6 [7] .
Publications starting from the year 2007 mostly concern multicentre, randomized, placebo-controlled studies on large groups of patients. The results show an important role of modafinil in improvement in terms of fatigue, comparable in unipolar an bipolar depression [14] [15] [16] . The efficacy of adjunctive modafinil was demonstrated in drug-resistant bipolar depression [17] , as well as the advantage of modafinil and armodafinil over other dopaminergic stimulants (methylphenidate, lisdexamphetamine, dexamphetamine, methylamphetamine, pemoline) in both types of depression, especially in terms of effects on fatigue and excessive sleepiness and cognitive impairment [15, 18] .
Atypical depression with excessive sleepiness and increased appetite
The efficacy of modafinil as monotherapy was studied in atypical depression with excessive sleepiness and increased appetite. A beneficial effect of modafinil has been reported during the 12-week open-label phase of the trial. The benefits were maintained during randomization in both groups. The authors particularly emphasized the role of modafinil in the reduction of body weight in patients with increased appetite [19] .
Seasonal/winter depression
In a study of 9 patients with seasonal/winter depression, modafinil has proven to be highly effective in improving the overall functioning (measured using the SIGH-SAD, the MADRS and the HAM-D scales), and in particular vigilance in the ESS and reduction of fatigue in the FSS [20] .
Major depressive disorder in somatic disorders
A large group of studies concerns the effects of modafinil on cancer-related fatigue in patients receiving chemotherapy. Conley et al. [21] studied 541 patients during chemotherapy with concomitant depression. A correlation between the severity of fatigue and the impact of modafinil on depressive symptoms was noticed -patients experiencing extreme fatigue (BFI ≥ 7) presented by far greater improvement in depressive symptoms.
Another important group are the patients with obstructive sleep apnea and concomitant depression or dysthymia. In a study by Krystal et al. [22] involving patients in serotonergic antidepressant monotherapy, armodafinil 200 mg daily or placebo was introduced. The authors demonstrated a significant positive impact of armodafinil on excessive sleepiness (ESS) and related improvement in overall functioning (CGI), without significant impact on depression [22] .
In studies of patients with neurological disorders (Parkinson's disease -PD, multiple sclerosis -MS, post-polio syndrome -PPS, traumatic brain injury -TBI) and concomitant depression, improvements in terms of fatigue in TBI and daytime sleepiness in PD were observed. There was no therapeutic effect of modafinil on mood disorders in any of the above disorders [2] .
Armodafinil in the treatment of bipolar disorder
The so far conducted multicenter, randomized controlled studies of armodafinil apply to depression in bipolar disorder type I. In augmentation armodafinil therapy (150mg daily) with already used mood-stabilizing treatment (lithium carbonate, olanzapine, valproate or risperidone), significant improvement in symptoms of major depressive disorder in the CGI and MADRS scales and in overall functioning in the GAF scale was shown. However, there were no statistically significant differences from placebo [23] [24] [25] [26] . In the extended 6-month open-label study by the same authors on the efficacy and safety of armodafinil, further improvement in depressive symptoms and overall functioning of patients was shown [27] .
Cognition disorders
Research on the effects of modafinil on cognitive functioning was conducted in different groups -healthy volunteers without sleep deprivation and patients with depression with a partial response to treatment and in remission. In a group of healthy volunteers the study by Müller et al. [3] included i.a. visuospatial and short-term maintenance of digit sequences tasks. Modafinil reduced the amount of errors in visuospatial tasks and improved short-term memory, but had no effect on attention processes [3] . In another randomized study in healthy volunteers, positive effects of modafinil on learning ability were evaluated [28] . In a pooled analysis of studies of healthy volunteers, Battleday and Brem [29] particularly emphasize the effects of modafinil on executive functions. In 35 patients with major depressive disorder with a partial response to antidepressant treatment, modafinil improved the Stroop Interference Test results, but showed no gains in other neuropsychological tests. There was no negative impact of modafinil on cognition [13] . In the latest study by Kaser et al. [30] on 60 patients with remitted depression receiving modafinil 200 mg daily, tested with a computerized neuropsychological battery CANTAB (Cambridge Neuropsychological Test Automated Battery), it has been proven that modafinil has a positive effect on working and episodic memory, but not on the planning processes and attention. In the literature, including the cited studies, the effect of modafinil on working and episodic memory was associated with noradrenergic and dopaminergic stimulation of the prefrontal cortex [3, 30, 31] . 
Apathy in elderly patients with depression and dementia
An increase in the dopaminergic transmission also leads to reduction of apathy. Case reports of apathy treatment with modafinil from 2007 (a patient with depression and dementia) and 2011 [32, 33] confirmed a greater effectiveness of modafinil compared with antidepressants in this disorder. Patients reported improvement of motivation and returned to their previous interests, pleasure activities and physical activity. Both articles presented elderly patients. An additional benefit of the use of modafinil in such patients is the lack of significant interactions with other medications.
Adrafinil
In the literature one can find individual reports from the 1980s till the year 2008 on adrafinil as a substance affecting cognition and behavior in animals (rodents, monkeys, Beagle dogs). Newer publications rather describe adrafinil detection methods used in forensics and sport and the use of adrafinil and its metabolites (modafinil and modafinil acid) as doping [34, 35] . To our best knowledge, there is no research on the role of adrafinil in mood disorders. Only French researchers described the positive impact of adrafinil on cognitive functioning (memory, attention and orientation) in people over the age of 50 with memory problems. However, any history of psychiatric disorders, including depression, was an exclusion criterion [36] . Table 2 shows collected results of the studies on the utility of eugeroics in the treatment of affective disorders. 
Conclusions
The use of modafinil in the world, including in Poland, raises a number of doubts. As a consequence, the usefulness of the drug tested in research in the above-mentioned situations is not reflected in therapeutic indications registered by the EMA (European Medicines Agency) and the FDA.
Adverse effects associated with the use of eugeroics in the aforementioned literature have been reported occasionally. Mostly headaches, dizziness, nausea, dry mouth, diarrhea, and insomnia -mild to moderate, were mentioned. In general, modafinil and armodafinil were defined as well-tolerated. Between 1998 and 2007 the FDA reported 6 cases of severe cutaneous hypersensitivity reactions, including erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome, and DRESS syndrome.
While using eugeroics the possibility of manic switch could seem an element of risk. In the light of the discussed studies, these concerns are not confirmed. None of them showed a relationship of eugeroics administration with sporadically occurring cases of manic, hypomanic or mixed phase switch because, if present, they were even rarer than those in the placebo group [17] . However, in the literature there are case reports of manic episode -in a boy treated with modafinil for narcolepsy [37] and in a woman with drug-resistant depression and anhedonia in the course of bipolar disorder, where withdrawal of modafinil caused mood stabilization [38] . Given that, modafinil treatment should always be considered individually.
Another problem with the use of modafinil is fear of addiction. The cited studies highlighted the attractiveness of modafinil compared to other stimulants due to its low addictive potential. Comparisons, for example, with cocaine or amphetamine and its derivatives appear unreasonable due to the high selectivity of modafinil in the CNS (hypothalamic nuclei and the amygdala) and low dopaminergic activity in the striatum [9, 17] . Both phase switch and tolerance or addiction have not been observed even in patients with a history of substance abuse [39] .
The status of modafinil in the world varies. It is a registered medicine, i.a., in dozens of European countries, in the USA, in Canada and in several Asian countries. In many countries (e.g., China, Japan, Russia) it is on the list of controlled substances alongside with amphetamine, cocaine, morphine, methylphenidate, and other stimulants. In general, it is a prescription drug registered for narcolepsy and in some countries also in shift-work sleep disorders and excessive daytime sleepiness associated with obstructive sleep apnea. According to the EMA directive from 2010, modafinil is only recommended for the treatment of narcolepsy [5] . In the light of the presented studies, eugeroics are useful in the treatment of mood disorders as monotherapy or as potentiation of antidepressant therapy. It appears that the use of modafinil in mood disorders brings the best results in short-term (up to 6 weeks) or rescue treatment. According to the authors, based on the results of research and practice, it could be possible to extend the list of indications for the use of eugeroics for those listed in Table 3 . Nevertheless, according to the principles of evidence-based medicine (EBM), eugeroics do not belong to the level I quality of evidence and level A recommendations category in these applications.
In Poland, after 10 years of modafinil presence on the market, its distribution has been withdrawn due to high price (over 1,500 PLN per month) and fruitless efforts to refund. At present, it is only possible to import modafinil preparations in individual cases, but without refund in mood disorders. In the situation of importing modafinil from Germany, the cost of a 3-month treatment is about 1,400 PLN. Patients traveling to other European countries have also the opportunity to fill Polish prescriptions at lower prices. On the other hand, frequently practiced import on one's own -for instance from the Internet -is uncertain and dangerous.
